Celgene Corporation (CELGZ) stock prices updated...
 

Celgene Corporation stock price

Celgene Corporation latest news:


  • 10/19/2017 15:36:36

    BRIEF-Celgene says net pre-tax charge to Q4 earnings estimated to be $300 mln to $500 mln

    * Celgene - concluded oct 18 will recognize q4 charge to earnings related to impairment of about $1,600 million ged-0301 IPR&D asset - sec filing

  • 10/19/2017 15:13:11

    Celgene shares drop after Crohn's disease drug trials halted

    Celgene Corp. shares dropped in the extended session Thursday after the biotech company said it would discontinue two clinical trials for a Crohn's disease treatment and not start a third. Celgene shares fell 6.2% to $127.55 after hours, following a brief halt. Based on an analysis from a data monitoring committee assessing overall benefit and risk, Celgene said it would discontinue a late-stage clinical trial for the drug GED-0301 to treat Crohn's disease along with an extension trial. Crohn's disease is characterized by a chronic inflammation that can run the entirety of the digestive tract. Celgene said it will also not start a third late-stage clinical trial of the drug for Crohn's disease. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/19/2017 14:38:03

    BRIEF-Celgene provides update on GED-0301 (mongersen) inflammatory bowel disease program

    * Celgene provides update on GED-0301 (mongersen) inflammatory bowel disease program

  • 09/07/2017 09:25:12

    Celgene Faces Multiple Clinical Holds From FDA


  • 08/28/2017 09:41:09

    Biotech stocks surge on Gilead's Kite Pharma acquisition

    After news of Gilead Sciences Inc.'s about $11 billion acquisition of Kite Pharma Inc. , Juno Therapeutics Inc. shares surged 16.3%, Bluebird Bio Inc. shares surged 9.7% and Cellectis SA ADR shares surged 11.8% in extremely heavy midday trade Monday. The Kite Pharma acquisition marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T-cell therapy, or CAR-T, which uses a patient's immune T-cells and re-engineers them to better fight cancer. Juno, Bluebird and Cellectis are other biotech companies working in CAR-T. BTIF analyst Dane Leone upgraded Juno on Monday, adding, "we continue to be skeptical of JUNO's current competitive positioning, but upgrade our ranking to Neutral from Sell, as there is not a near term catalyst to offset the positive tailwind for the entire CAR T space." Though there has been speculation about Celgene -- which owns about 10% of Juno's current shares outstanding -- acquiring Juno, "we would be surprised" by a full acquisition, Leone said, since "at this juncture with emerging overlap in Multiple Myeloma and third to market status in CD19 hematological malignancies, we struggle to find a rationale for Celgene wanting to fully own Juno." Kite Pharma shares surged 28% in extremely heavy morning trade. Shares have surged 144% over the last three months, compared with a 1% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/10/2017 11:39:46

    BRIEF-Celgene Corp says on August 10, co issued $500 million aggregate principal amount of 2.250% senior notes due 2021

    * Celgene Corp - on August 10, 2017, co issued $500 million aggregate principal amount of 2.250% senior notes due 2021 - SEC filing Source text - (http://bit.ly/2hNCc4D) Further company coverage:

  • 08/01/2017 11:50:59

    BRIEF-Celgene says monthly wholesale acquisition cost of AML treatment Idhifa is $24,872

    * Says monthly wholesale acquisition cost of AML treatment Idhifa is $24,872 Further company coverage:

  • 08/01/2017 09:21:18

    FDA approves leukemia treatment developed by Celgene, Agios

    Aug 1 (Reuters) - The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's treatment for acute myeloid leukemia (AML) patients with a specific genetic mutation.

  • 07/25/2017 18:42:49

    Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

    The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.

  • 07/25/2017 14:57:25

    Celgene Corp. to pay $280 million to settle lawsuit alleging it promoted cancer drugs for unapproved uses

    Celgene Corp. to pay $280 million to settle lawsuit alleging it promoted cancer drugs for unapproved uses.

  • More trends:

    Celladon CorporationCLDN | Celldex Therapeutics, Inc.CLDX | Cellectar Biosciences, Inc.CLRB | Cellectar Biosciences, Inc.CLRBW | Cellectis S.A.CLLS | Cellular Biomedicine Group, Inc.CBMG | Celsion CorporationCLSN | Celsus Therapeutics PlcCLTX | Celyad SACYAD | Cempra, Inc.CEMP |